Sermaglutide

Product Details

CAS910463-68-2

Molecular formula C187H291N45O59

Molecular weight 4113.58

MOL file 910463-68-2.mol

Storage conditions -20 ° C storage

Solubility DMSO: 3mg/mL (0.73 mM)

brief introduction

Somaglutide is a new generation of GLP-1 (glucagon like peptide-1) analog developed by Daminol and NovoNordisk. Somaglutide is a long-term dosage form developed based on the basic structure of Lilalutide, which has better effect in the treatment of type 2 diabetes. Novo Nordisk has completed six PhaseIIIa studies on Somaglutide injection, and submitted a new drug registration application for Somaglutide injection once a week to the US Food and Drug Administration (FDA) on December 5, 2016, and also submitted a marketing authorization application (MAA) to the European Drug Administration (EMA). On the other hand, the daily oral preparation of Somaglutide is currently in clinical phase III.

effect

Somaglutide is a long-acting dosage form developed based on the basic structure of liraglutide, which has better effect in the treatment of type 2 diabetes.

Preparation

Somaglutide was prepared by solid-liquid phase synthesis method. Solid phase synthesis method was used to prepare linear peptides Aib8, Arg34GLP-1 (7-37), as well as fatty side chain acylating agents. Under alkaline conditions, the synthesized fatty chain acylating agent was used to modify the linear peptide Lys26 to obtain Somaglutide. The biological activity of the self-made samples was determined by time-resolved fluorescence resonance energy transfer immunoassay.